US FDA Holds First Hybrid Meeting With Industry
A Type A meeting was held in-person with a virtual contingent, the FDA clarified to the Pink Sheet. Several other meeting requests received were eligible, but did not seek an in-person session.
You may also be interested in...
Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More
Short stories about how US FDA’s conference center changed since COVID-19 forced the end of in-person public events, what the agency did to officially close the books on Makena, and more.
Supplemental Filings: Pink Sheet’s Notebook on Elon vs. FDA, Audio vs. Video, and More
Califf tweaks his misinformation stump speech, FDA adds to the Twitter COVID vaccine confusion with a tweet to Elon Musk, generic firms are schooled on the difference between a teleconference and a video conference, and other observations from Pink Sheet reporters’ notebooks.
US FDA Expands In-Person Meeting Eligibility, But So Far No Takers
The agency has not scheduled a hybrid meeting (with some staff meeting in person and others joining via videoconference) since allowing the format in mid-February.